Otsuka Pharmaceutical Reports OLE Study Data on Repinatrabit in Phenylketonuria

Why It Matters

The data suggest repinatrabit could become the first oral therapy to substantially lower phenylalanine in a broad PKU population, potentially reshaping standard care and expanding market opportunities.

Key Takeaways

• 75 mg repinatrabit cut phenylalanine 67% in adolescents
• All patients responded, including sapropterin non‑responders
• Second cohort will evaluate 150 mg dose
• Phase III PheORD trial enrolls 120 adults, results 2026
• Data presented at ACMG’26, signaling regulatory interest

Pulse Analysis

Phenylketonuria remains a lifelong metabolic disorder where dietary restriction is the cornerstone of management, yet adherence challenges drive demand for pharmacologic alternatives. Existing options such as sapropterin benefit only a subset of patients with residual enzyme activity, leaving a sizable unmet need for agents that can reliably lower phenylalanine across genotypes. Repinatrabit, an oral small‑molecule that enhances phenylalanine catabolism, enters this space with a novel mechanism that could complement or replace dietary therapy for many.

The OLE cohort’s 67% mean phenylalanine reduction after just eight weeks signals a robust pharmacodynamic effect, especially notable because efficacy was observed in individuals previously unresponsive to sapropterin. This breadth of response hints at a disease‑modifying potential that could broaden the treatable PKU population. Moreover, the upcoming 150 mg dose escalation will test whether a higher exposure can deepen and sustain reductions, a critical factor for long‑term metabolic control and quality‑of‑life improvements.

Looking ahead, the Phase III PheORD trial’s randomized, crossover design will generate pivotal comparative data against placebo, with a primary endpoint slated for late 2026. Successful outcomes could accelerate regulatory filings and position repinatrabit as a first‑in‑class oral PKU therapy, challenging incumbent products and attracting payer interest. The concurrent presentation at ACMG’26 underscores growing clinical enthusiasm, suggesting that Otsuka may soon leverage this momentum to secure market exclusivity and address a sizable global PKU cohort.